Known, approved drugs ranked as repurposing candidates for Juvenile Dermatomyositis — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.
Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S3 (505(b)(2)+Orphan) regulatory framing · structure-function intelligence.
Acquire dossier — $3,950